Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Atom Bioworks Inc. is active in the Biotechnology & Pharmaceuticals technology area, where it currently has 1 pending office action. The prosecution of this portfolio is handled by 1 distinct examiner, indicating a focused engagement with the patent office. This concentration suggests that the company's current intellectual property strategy is centered on a specific biological or pharmaceutical innovation.
The activity is restricted to 1 distinct art unit, which highlights the specialized nature of the technology under review. YU, DAVID TUYANG is the busiest examiner for the portfolio, with 1 pending office action currently assigned. Since the company only has 1 pending office action in total, this examiner is the sole individual responsible for reviewing the company's active patent applications in the Biotechnology & Pharmaceuticals field.
Practitioners should note that having 1 distinct examiner and 1 distinct art unit streamlines the prosecution process. The workload of 1 pending office action for YU, DAVID TUYANG represents the entire active portfolio, allowing for a concentrated effort to address the examiner's specific concerns. This focused environment in the Biotechnology & Pharmaceuticals sector simplifies the coordination of responses and the tracking of prosecution milestones.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YU, DAVID TUYANG | 1 | 100.0% | +0.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18705089 | MULTISPECIFIC POLYNUCLEOTIDE NANOSTRUCTURES FOR CANCER DETECTION AND THERAPY | YU, DAVID TUYANG | — |
| Art Unit | Apps |
|---|---|
| 1635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18705089 | MULTISPECIFIC POLYNUCLEOTIDE NANOSTRUCTURES FOR CANCER DETECTION AND THERAPY | YU, DAVID TUYANG | 1635 | §102§103DP | Non-Final OA | — | Pending | Apr 26, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAtom Bioworks Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
David Tuyang Yu has the most, with 1 of Atom Bioworks Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.